REGISTER
Prof. Michiel S. van der Heijden on Emerging Immunotherapy Strategies in Bladder Cancer
Prof. van der Heijden provides an in-depth interpretation of the latest advances in bladder cancer immunotherapy.

Prof. Michiel S. van der Heijden, Netherlands Cancer Institute, the Netherlands

Prof. van der Heijden provides an in-depth interpretation of the latest advances in bladder cancer immunotherapy, including data from the KEYMAKER-U04 subgroup study (04B) evaluating a triplet treatment regimen. He also discusses emerging strategies for personalized bladder-preservation approaches based on circulating tumor DNA (ctDNA) and urine tumor DNA biomarkers, highlighting both the clinical potential and the practical challenges of implementing these precision approaches.

Watch the full interview for detailed insights and expert perspectives.

0
0
Loading